US regulatory status: approved.
biotech · Chronic Hepatitis B · Chronic Hepatitis B Infection · ALGS
Aligos Therapeutics
Aligos Therapeutics drug portfolio — 10 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
1 Corporate Dr, South San Francisco, California 94080, US HQ
2018 Founded
98 Employees
Public company Type
ALGS · NYSE Ticker
Company details
- Status
- Public
- HQ
- 1 Corporate Dr, South San Francisco, California 94080, US
- Founded
- 2018
- Employees
- 98
- Programs
- 14
- Drugs
- 10
- Patents
- 32
Aligos Therapeutics pipeline
Portfolio lens on 10 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Aligos Therapeutics drug portfolio — 10 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Voltage-gated L-type calcium channel.
- Target
- Voltage-gated L-type calcium channel
- Mechanism
- Voltage-gated L-type calcium channel blocker
-
Development asset linked to Aligos Therapeutics in public FDA and regional records. Mechanism: HMG-CoA reductase inhibitor.
- Mechanism
- HMG-CoA reductase inhibitor
-
US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker
-
covid-19 vaccine (inactivated, adjuvanted, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Aligos Therapeutics's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
Development asset linked to Aligos Therapeutics in public FDA and regional records.
-
Development asset linked to Aligos Therapeutics in public FDA and regional records.
-
Development asset linked to Aligos Therapeutics in public FDA and regional records.
-
Development asset linked to Aligos Therapeutics in public FDA and regional records.
-
tenofovir disoproxil
Antiinfectives for systemic use (J05)Antiinfectives for systemic use (J05) compound in Aligos Therapeutics's portfolio.